The selection of patients is crucial, as patients candidates for transplant must have non-resectable disease limited to the liver with favorable molecular prognosis markers (patients with V600 BRAF mutant CRC are excluded, due to their poor prognosis, while high microsatellite instability and deficient DNA mismatch repair are also excluded, but due to the notable results of immunotherapy in this population and concerns about the high allograft rejection rate associated with the administration of immunotherapy after solid organ transplantation). This evidence concerns the gene BRAF and colorectal carcinoma.